Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Buske

Showing results (141-150 of 148) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 148 results.
Nature|December 8, 2016
A 17-gene stemness score for rapid determination of risk in acute leukaemiaStanley W K Ng, Amanda Mitchell, James A Kennedy, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Blood|July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN StudyMeletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
Blood Advances|July 11, 2022
Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IVG Tjitske Los-de Vries, Wendy B C Stevens, Erik van Dijk, et al.
Blood Advances|February 5, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemiaConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Blood Cancer Discovery|December 5, 2025
Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic LeukemiaMark Hartmann, Maximilian Schönung, Jovana Rajak, et al.
Leukemia|October 3, 2018
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 studyJan Braess, Susanne Amler, Karl-Anton Kreuzer, et al.
Pageof 15

Showing results (141-150 of 148) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 148 results.
Nature|December 8, 2016
A 17-gene stemness score for rapid determination of risk in acute leukaemiaStanley W K Ng, Amanda Mitchell, James A Kennedy, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Blood|July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN StudyMeletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
Blood Advances|July 11, 2022
Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IVG Tjitske Los-de Vries, Wendy B C Stevens, Erik van Dijk, et al.
Blood Advances|February 5, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemiaConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Blood Cancer Discovery|December 5, 2025
Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic LeukemiaMark Hartmann, Maximilian Schönung, Jovana Rajak, et al.
Leukemia|October 3, 2018
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 studyJan Braess, Susanne Amler, Karl-Anton Kreuzer, et al.
Pageof 15